Analysis Tools
phenotype not analyzed
|
• mice were only used to create the germline recombined allele
|
|
Allele Symbol Allele Name Allele ID |
Prdm1tm2Masu targeted mutation 2, M Azim Surani MGI:3703794 |
||||||||||||||||
| Summary |
3 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice were only used to create the germline recombined allele
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• hepatomegaly in one mouse
|
|
• splenomegaly in all terminally ill mice
|
|
• splenomegaly in all terminally ill mice
|
|
• plasma cell formation is severely impeded 10 days after primary and secondary immunization
|
|
• mice show increased numbers of germinal center B cells at day 10 after primary immunizations
|
|
• small, but significant, increase of the fraction of germinal center B cells in the S and G2 phases of the cell cycle
|
|
• reduction in total as well as sheep red blood cell-specific IgG1, but not IgM, antibodies 10 days after primary and secondary immunization
|
|
• splenomegaly in all terminally ill mice
|
|
• plasma cell formation is severely impeded 10 days after primary and secondary immunization
|
|
• mice show increased numbers of germinal center B cells at day 10 after primary immunizations
|
|
• small, but significant, increase of the fraction of germinal center B cells in the S and G2 phases of the cell cycle
|
|
• reduction in total as well as sheep red blood cell-specific IgG1, but not IgM, antibodies 10 days after primary and secondary immunization
|
|
• occasional lymphadenopathy
|
|
• hepatomegaly in one mouse
|
|
• shortened survival
|
|
• shortened survival
|
|
• spleens and lymph nodes show presence of large cells with a diffuse growth pattern, resembling diffuse large B cell lymphoma (DLBCL)
• lymphoproliferations are of clonal origin
• 5 of 6 DLBCLs are consistent with activated B cell-DLBCL
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• plasma cell formation is severely impeded 10 days after primary and secondary immunization
|
|
• mice show increased numbers of germinal center B cells at day 10 after primary immunizations
|
|
• small, but significant, increase of the fraction of germinal center B cells in the S and G2 phases of the cell cycle
|
|
• reduction in total as well as sheep red blood cell-specific IgG1, but not IgM, antibodies 10 days after primary and secondary immunization
|
|
• plasma cell formation is severely impeded 10 days after primary and secondary immunization
|
|
• mice show increased numbers of germinal center B cells at day 10 after primary immunizations
|
|
• small, but significant, increase of the fraction of germinal center B cells in the S and G2 phases of the cell cycle
|
|
• reduction in total as well as sheep red blood cell-specific IgG1, but not IgM, antibodies 10 days after primary and secondary immunization
|
|
• shortened survival, with 40% survival at around 500 days of age
|
|
• mice succumb to a B cell-derived lymphoproliferative disease affecting spleen and lymph nodes, resembling human diffuse large B cell lymphoma
• mice develop clonal lymphomas consistent with activated B cell-diffuse large B cell lymphoma
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| non-Hodgkin lymphoma | DOID:0060060 |
OMIM:605027 |
J:167612 | |
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Copyright, and Privacy Statement Send questions and comments to User Support. |
last database update 05/24/2023 MGI 6.22 |
|
|
|
||